Volume 4, Issue 4 (2018)                   Pharm Biomed Res 2018, 4(4): 13-18 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghadlinge M, Rana P. The progress in new drug approvals for infective disease of poverty (IDOP) in India. Pharm Biomed Res. 2018; 4 (4) :13-18
URL: http://pbr.mazums.ac.ir/article-1-209-en.html
1- Department of pharmacology, PGIMER and Dr RML Hospital, New Delhi, India
Abstract:   (1482 Views)
The global burden for infectious disease remains high in the developing and underdeveloped countries like Sub-Sahara Africa, South–East Asia and Latin America. Among them, the three major contributors of mortality and morbidity are HIV/AIDS, tuberculosis and malaria which along with neglected tropical diseases (NTDs) are collectively known as “infectious diseases of poverty” (IDoP). There is the strong pressing need for developing new drug molecules for eradication of these diseases. We did a cross-sectional study as per the STROBE guidelines to compare the disease burden and new drug approved for IDoP in India. The findings of this study show that new drugs approvals in India has restricted to the non-communicable diseases only.  This mismatch becomes even more apparent for communicable diseases included under IDOP which had only 2.7% share among the total new drug approved during year 2000 to 2017 and only half of them were true innovator drugs. This shows the urgent need to allocate research resources in sync with the existing burden of disease in India and to promote research and development for diseases which affect poor people of country and are neglected by the world.
Full-Text [PDF 867 kb]   (1269 Downloads)    
Type of Study: Original Research | Subject: Clinical Pharmacy

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb